The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Moshe MittelmanThe MDS Hub was pleased to speak to Moshe Mittelman, Tel Aviv University, Tel Aviv, IL. We asked, What is the sequence of therapy in myelodysplastic syndromes (MDS)?
Sequence of therapy in myelodysplastic syndromes
Mittelman begins by explaining how the sequence of therapy is dependant on the individual patient's risk classification. Mittelman goes on to discuss response rates for different drugs including lenalidomide and erythroid-stimulating agents. Finally, Mittelman discusses drugs currently under investigation, and using stem cell transplant (SCT) as a possible approach in the future.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content